0001295947false00012959472025-02-062025-02-06


 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): February 6, 2025

 
PRESTIGE CONSUMER HEALTHCARE INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware001-3243320-1297589
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

 
660 White Plains Road, Tarrytown, New York 10591
(Address of Principal Executive Offices) (Zip Code)
 
(914) 524-6800
(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per sharePBHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging Growth Company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐



Item 2.02 Results of Operations and Financial Condition.
 
On February 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and nine months ended December 31, 2024. A copy of the press release announcing the Company's earnings results for the fiscal quarter and nine months ended December 31, 2024 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On February 6, 2025, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and nine months ended December 31, 2024 using slides attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”) and incorporated herein by reference.  The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2025.
 
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
 
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.
 
(d)    Exhibits.
 
See Exhibit Index immediately following the signature page.

 



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: February 6, 2025PRESTIGE CONSUMER HEALTHCARE INC. 
    
 By:/s/ Christine Sacco 
  Christine Sacco 
  Chief Financial Officer & Chief Operating Officer 



 
EXHIBIT INDEX


Exhibit 99.1


Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook

◦Revenue of $290.3 million in Q3, up 2.7% versus prior year
◦Diluted EPS of $1.22 in Q3 increased approximately 15% versus prior year
◦Reduced leverage to 2.5x in Q3, driven by strong profitability and cash flow
◦Raising full-year fiscal 2025 earnings outlook

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-February 6, 2025-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024.

“We are pleased with our strong third quarter results that delivered both record quarterly sales and earnings per share. Sales trends benefitted from continued strong International business performance and was further helped by sequentially improved Clear Eyes® revenues. Continued robust free cash flow enabled us to pay off all remaining variable debt, allowing for further capital allocation opportunities to drive shareholder value as we approach fiscal 2026,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Third Fiscal Quarter Ended December 31, 2024

Reported revenues in the third quarter of fiscal 2025 of $290.3 million increased 2.7% from $282.7 million in the third quarter of fiscal 2024. The revenue performance versus the prior year comparable period reflected continued strong growth in the International OTC segment, partially offset by declines in the Cough & Cold category. The revenue performance also included sequential sales improvement versus second quarter fiscal 2025 for Clear Eyes.

Reported net income for the third quarter of fiscal 2025 totaled $61.0 million compared to the prior year third quarter of $53.0 million. Diluted earnings per share of $1.22 for the third quarter of fiscal 2025 compared to $1.06 in the prior year comparable period.

Nine Months Ended December 31, 2024

Reported revenues for the first nine months of fiscal 2025 totaled $841.2 million and compared to revenues of $848.4 million for the first nine months of fiscal 2024. Revenues decreased 0.8% versus the prior year comparable period. The revenue performance for the first nine months reflected the anticipated limited ability to supply strong demand for Clear Eyes and declines in the Cough & Cold and Women’s Health categories, partially offset by continued strong growth in the Gastrointestinal category and International OTC segment.

Reported net income for the first nine months of fiscal 2025 totaled $164.5 million, or $160.4 million on a non-GAAP adjusted basis, versus the prior year comparable period net income of $159.9 million. Diluted earnings per share and non-GAAP adjusted diluted earnings per share were $3.28 and $3.20, respectively, for the first nine months of fiscal 2025, compared to diluted earnings per share of $3.19 in the prior year comparable period.








The adjustment to the first nine months of fiscal 2025 relates to a discrete tax item in the first quarter pertaining to the release of a reserve for an uncertain tax position due to the statute of limitations expiring.


Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for the third quarter of fiscal 2025 was $65.1 million compared to $71.5 million during the prior year comparable period. Non-GAAP free cash flow in the third quarter of fiscal 2025 of $63.5 million decreased compared to $69.5 million in the prior year third quarter. The Company's net cash provided by operating activities for the first nine months of fiscal 2025 was $189.7 million, compared to $182.0 million during the prior year comparable period. Non-GAAP free cash flow in the first nine months of fiscal 2025 was $184.9 million, increasing compared to $175.6 million in the prior year comparable period.

In the first nine months of fiscal 2025, the Company repurchased approximately 0.6 million shares at a total investment of approximately $40.2 million. The Company's net debt position as of December 31, 2024 was approximately $0.9 billion, resulting in a covenant-defined leverage ratio of 2.5x.

Segment Review

North American OTC Healthcare: Segment revenues of $238.9 million for the third quarter fiscal 2025 increased 1.0% compared to the prior year comparable quarter's segment revenues of $236.6 million. The revenue increase reflected strong GI and Dermatologicals category growth, partially offset by declines in the Cough & Cold category.

For the first nine months of the current fiscal year, reported revenues for the North American OTC Healthcare segment were $711.1 million, which compared to $727.1 million in the prior year comparable period. The change was attributable to higher GI category sales offset by lower sales in the Cough & Cold, Women’s Health, and Oral Care categories, as well as the limited ability to fully supply demand for Clear Eyes.

International OTC Healthcare: Fiscal third quarter 2025 revenues of $51.4 million increased 11.3% compared to $46.2 million reported in the prior year comparable period, and increased 8.3% excluding the effects of foreign currency. The performance was driven by broad-based growth in Australia revenues led by the Hydralyte® brand.

For the first nine months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $130.2 million, an increase of approximately 7.4% over the prior year comparable period’s revenues of $121.2 million, or approximately 6.2% excluding the effects of foreign currency. The revenue growth was led by strong growth for the Hydralyte brand.

Commentary and Updated Outlook for Fiscal 2025

Ron Lombardi, Chief Executive Officer, stated, “We are pleased with third quarter performance that delivered improved revenue trends for Summer’s Eve and Clear Eyes, as well as double-digit earnings growth, resulting from the benefits of our strong free cash flow that enabled debt reduction and share repurchases. Looking at the full-year fiscal 2025, our sales performance year-to-date sets us up well to achieve our fiscal 2025 outlook and for approximately 1% organic revenue growth. Regarding







profitability, we are raising our earnings outlook thanks to our strong free cash flows that enabled lower interest expense and shares outstanding.”

“Our proven business strategy continues to deliver strong financial performance and leaves us well positioned to deliver additional shareholder value through our anticipated robust long-term free cash flow generation,” Mr. Lombardi concluded.
Prior Fiscal 2025 Outlook
Current Fiscal 2025 Outlook
Revenue
$1,125 to $1,140 million$1,128 to $1,132 million
Organic Revenue Growth
Approximately 1%Approximately 1%
Adjusted Diluted E.P.S.
$4.40 to $4.46Approximately $4.50
Free Cash Flow
$240 million or more$240 million or more


Fiscal Third Quarter 2025 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its third quarter fiscal 2025 results today, February 6, 2025 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," "expect," "anticipate," “positioned,” “further” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and free cash flow the timing and extent of supply chain challenges, and the Company’s ability to maximize shareholder value through its business strategy, generation of free cash flow and capital allocation opportunities. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those







expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, evolving U.S. and international tariffs, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.








Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income and Comprehensive Income
(Unaudited)

 Three Months Ended December 31, Nine Months Ended December 31,
(In thousands, except per share data)2024 20232024 2023
Total Revenues$290,317  $282,741 $841,244 $848,366 
Cost of Sales   
Cost of sales excluding depreciation127,360  122,794 370,098  369,772 
Cost of sales depreciation1,908 2,009 6,693 5,963 
Cost of sales129,268 124,803 376,791 375,735 
Gross profit161,049  157,938 464,453  472,631 
Operating Expenses   
Advertising and marketing37,945  39,466 118,719  115,799 
General and administrative26,182  26,003 81,159  79,687 
Depreciation and amortization4,960  5,637 16,228  16,869 
Total operating expenses69,087  71,106 216,106  212,355 
Operating income91,962  86,832 248,347  260,276 
Other expense   
Interest expense, net11,455 16,575 36,873 51,900 
Other expense (income), net353 682 1,244 (327)
Total other expense, net11,808  17,257 38,117  51,573 
Income before income taxes80,154 69,575 210,230 208,703 
Provision for income taxes19,122  16,529 45,753  48,822 
          Net income $61,032  $53,046 $164,477  $159,881 
Earnings per share:   
Basic$1.23  $1.07 $3.31  $3.21 
Diluted$1.22  $1.06 $3.28  $3.19 
Weighted average shares outstanding:   
Basic49,597  49,740 49,711  49,731 
Diluted49,993  50,125 50,085  50,134 
Comprehensive income, net of tax:
Currency translation adjustments(13,628)7,465 (5,669)3,035 
Total other comprehensive (loss) income(13,628)7,465 (5,669)3,035 
Comprehensive income$47,404 $60,511 $158,808 $162,916 








Prestige Consumer Healthcare Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
December 31, 2024March 31, 2024
Assets
Current assets
Cash and cash equivalents$50,874 $46,469 
     Accounts receivable, net of allowance of $16,667 and $16,377, respectively
167,274 176,775 
Inventories151,516 138,717 
Prepaid expenses and other current assets7,500 13,082 
Total current assets377,164 375,043 
Property, plant and equipment, net73,524 76,507 
Operating lease right-of-use assets29,658 11,285 
Finance lease right-of-use assets, net4,943 1,541 
Goodwill527,219 527,733 
Intangible assets, net2,310,650 2,320,583 
Other long-term assets6,339 5,725 
Total Assets$3,329,497 $3,318,417 
Liabilities and Stockholders' Equity  
Current liabilities  
Accounts payable19,506 38,979 
Accrued interest payable15,206 15,763 
Operating lease liabilities, current portion6,018 4,658 
Finance lease liabilities, current portion900 1,494 
Other accrued liabilities60,915 56,154 
Total current liabilities102,545 117,048 
Long-term debt, net991,969 1,125,804 
Deferred income tax liabilities413,276 403,596 
Long-term operating lease liabilities, net of current portion24,168 7,528 
Long-term finance lease liabilities, net of current portion4,077 172 
Other long-term liabilities5,029 9,185 
Total Liabilities1,541,064 1,663,333 
Total Stockholders' Equity1,788,433 1,655,084 
Total Liabilities and Stockholders' Equity$3,329,497 $3,318,417 























Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Nine Months Ended December 31,
(In thousands)2024 2023
Operating Activities 
Net income $164,477 $159,881 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization22,921 22,832 
Loss on disposal of property and equipment83 231 
Deferred and other income taxes7,278 14,892 
Amortization of debt origination costs1,316 3,726 
Stock-based compensation costs8,424 10,283 
Non-cash operating lease cost5,322 4,494 
Changes in operating assets and liabilities:
Accounts receivable8,874 (7,017)
Inventories(13,385)13,790 
Prepaid expenses and other current assets5,558 (2,605)
Accounts payable(18,851)(23,964)
Accrued liabilities4,359 (7,732)
Operating lease liabilities(5,721)(5,259)
Other(988)(1,533)
Net cash provided by operating activities189,667  182,019 
Investing Activities   
Purchases of property, plant and equipment(4,745)(6,407)
Acquisition and other(9,228)1,300 
Net cash used in investing activities(13,973) (5,107)
Financing Activities   
Term loan repayments(135,000)(150,000)
Payments of debt costs— (769)
Payments of finance leases(1,899)(2,112)
Proceeds from exercise of stock options12,340 10,818 
Fair value of shares surrendered as payment of tax withholding(5,832)(5,508)
Repurchase of common stock(40,196)(25,000)
Net cash used in financing activities(170,587) (172,571)
Effects of exchange rate changes on cash and cash equivalents(702)785 
Increase in cash and cash equivalents4,405  5,126 
Cash and cash equivalents - beginning of period46,469 58,489 
Cash and cash equivalents - end of period$50,874  $63,615 
Interest paid$37,427 $49,666 
Income taxes paid$33,512 $38,606 







Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income
Business Segments
(Unaudited)

 
Three Months Ended December 31, 2024
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Total segment revenues*$238,934 $51,383 $290,317 
Cost of sales108,067 21,201 129,268 
Gross profit130,867 30,182 161,049 
Advertising and marketing30,995 6,950 37,945 
Contribution margin$99,872 $23,232 $123,104 
Other operating expenses 31,142 
Operating income $91,962 
*Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.

 Nine Months Ended December 31, 2024
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Total segment revenues*$711,061 $130,183 $841,244 
Cost of sales321,408 55,383 376,791 
Gross profit389,653 74,800 464,453 
Advertising and marketing99,637 19,082 118,719 
Contribution margin$290,016 $55,718 $345,734 
Other operating expenses 97,387 
Operating income $248,347 
*Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.































 
Three Months Ended December 31, 2023
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Total segment revenues*$236,565 $46,176 $282,741 
Cost of sales106,090 18,713 124,803 
Gross profit 130,475 27,463 157,938 
Advertising and marketing33,917 5,549 39,466 
Contribution margin$96,558 $21,914 $118,472 
Other operating expenses 31,640 
Operating income $86,832 
*Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.
 
Nine Months Ended December 31, 2023
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Total segment revenues*$727,131 $121,235 $848,366 
Cost of sales323,632 52,103 375,735 
Gross profit 403,499 69,132 472,631 
Advertising and marketing100,707 15,092 115,799 
Contribution margin$302,792 $54,040 $356,832 
Other operating expenses 96,556 
Operating income $260,276 
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.









About Non-GAAP Financial Measures
In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.
These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.
NGFMs Defined
We define our NGFMs presented herein as follows:
•Non-GAAP Organic Revenues: GAAP Total Revenues excluding the impact of foreign currency exchange rates in the periods presented.
•Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.
•Non-GAAP EBITDA: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.
•Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.
•Non-GAAP Adjusted Net Income: GAAP Net Income adjusted for a normalized tax rate.
•Non-GAAP Adjusted Diluted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted
weighted average number of shares outstanding during the period.
•Non-GAAP Free Cash Flow: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.
•Net Debt: Calculated as total principal amount of debt outstanding ($1,000,000 at December 31, 2024) less cash and cash equivalents ($50,874 at December 31, 2024). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.








Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:
Three Months Ended December 31, Nine Months Ended December 31,
2024202320242023
(In thousands)
GAAP Total Revenues$290,317 $282,741 $841,244 $848,366 
Revenue Change2.7 %(0.8)%
Adjustments:
Impact of foreign currency exchange rates— 1,114 — 780 
Total adjustments— 1,114 — 780 
Non-GAAP Organic Revenues$290,317 $283,855 $841,244 $849,146 
Non-GAAP Organic Revenue Change2.3 %(0.9)%
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin:
Three Months Ended December 31, Nine Months Ended December 31,
2024202320242023
(In thousands)
GAAP Net Income $61,032  $53,046 $164,477  $159,881 
Interest expense, net11,455 16,575 36,873 51,900 
Provision for income taxes19,122  16,529 45,753  48,822 
Depreciation and amortization6,868 7,646 22,921 22,832 
Non-GAAP EBITDA$98,477 $93,796 $270,024 $283,435 
Non-GAAP EBITDA Margin33.9 %33.2 %32.1 %33.4 %


Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:
Three Months Ended December 31, Nine Months Ended December 31,
20242024 Diluted EPS20232023 Diluted EPS20242024 Diluted EPS20232023 Diluted EPS
(In thousands, except per share data)
GAAP Net Income and Diluted EPS$61,032 $1.22 $53,046 $1.06 $164,477 $3.28 $159,881 $3.19 
Adjustments:
Normalized tax rate adjustment (1)
— — — — (4,030)(0.08)— — 
Total adjustments— — — — (4,030)(0.08)— — 
Non-GAAP Adjusted Net Income and Adjusted Diluted EPS$61,032 $1.22 $53,046 $1.06 $160,447 $3.20 $159,881 $3.19 
(1) Income tax adjustment to adjust for discrete income tax items.








Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow:
Three Months Ended December 31, Nine Months Ended December 31,
2024202320242023
(In thousands)
GAAP Net Income $61,032  $53,046 $164,477  $159,881 
Adjustments:
Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows14,973 18,408 45,344 56,458 
Changes in operating assets and liabilities as shown in the Statement of Cash Flows(10,914)18 (20,154)(34,320)
Total adjustments4,059 18,426 25,190 22,138 
GAAP Net cash provided by operating activities65,091 71,472 189,667 182,019 
Purchases of property and equipment(1,566)(1,996)(4,745)(6,407)
Non-GAAP Free Cash Flow$63,525 $69,476 $184,922 $175,612 


Outlook for Fiscal Year 2025:

Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:
Projected FY'25 GAAP Diluted EPS$4.58 
Adjustments:
Normalized tax rate adjustment (1)
(0.08)
Projected FY'25 Non-GAAP Adjusted Diluted EPS$4.50 
(1) Income tax adjustment to adjust for discrete income tax items.


Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow:
(In millions)
Projected FY'25 GAAP Net cash provided by operating activities$250 
Additions to property and equipment for cash(10)
Projected FY'25 Non-GAAP Free Cash Flow$240 







Third Quarter FY 2025 Results February 6th, 2025 Exhibit 99.2

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, and free cash flow; the Company’s ability to execute on its brand-building strategy and to drive free cash flow and maximize shareholder value; the Company’s expected earnings growth; and the Company’s capital allocation strategy and optionality, including its pursuit of M&A and share buybacks. Words such as “continue,” “expect,” “remain,” “going forward,” “proven,” “outlook,” “will,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages; the impact of economic and business conditions; consumer trends; competitive pressures; the impact of the Company’s advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; evolving U.S. and international tariffs; and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise. All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our February 6, 2025 earnings release in the “About Non-GAAP Financial Measures” section. Safe Harbor Disclosure 2

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Agenda for Today’s Discussion 3 I. Performance Update II. Financial Overview III. FY25 Outlook

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S I. Performance Update

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Record Results in Third Quarter FY 25 ◼ Record quarterly revenue of $290.3 million, ahead of expectations ◼ Outperformance highlighted by strong International growth ◼ Positive trends in Women’s Health and Clear Eyes®, as expected ◼ Gross Margin performance stable ◼ Diluted EPS up 15% versus prior year ◼ Continued strong financial profile and resulting Free Cash Flow(3) generation ◼ Leverage of 2.5x(3) continues to enable capital allocation optionality ◼ Reduced variable debt balance to zero and opportunistically repurchased shares ◼ M&A and share buybacks remain key optimal capital allocation levers Q3 FY 25 Sales Drivers Disciplined Capital Allocation Superior Earnings and FCF 5

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Comprehensive GI Portfolio Highlights Brand-Building Capabilities 6 Key Drivers Brand-Building Driving Consumption GrowthIconic GI Solutions Brand- uilding Driving Cate ory Leadership & Growth #1 Rectal laxative at retail1 #1 Motion sickness & nausea brand at retail1 #1 Upset stomach remedy at Canada retail1 1. Q3 IRI MULO+C as of 12/29/24, Gaviscon source Nielsen IQ Canada period ended 11/23/24 2. Annual Sales TTM ended 12/31 Strong Consumption Growth Driving +5% 3-Year CAGR2 Campaigns & Content Insight Driven Innovation Delivering on consumer needs Expanding consumer need states

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S II. Financial Overview

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Third Quarter and YTD FY25 Performance Highlights FY25 FY24 Dollar values in millions, except per share data. $290.3 $ 98.5 $1.22 $282.7 $93.8 $1.06 Revenue EBITDA Diluted EPS 2.7% 5.0% 15.1% 8 Q 3 $841.2 $270.0 $3.20 $848.4 $283.4 $3.19 Revenue EBITDA Adj. Diluted EPS (0.8%) (4.7%) 0.3% Record revenue of $290.3 million, up 2.7% vs. PY Record EPS of $1.22 up 15.1% vs. PY EBITDA(3) of $98.5 million, up 5.0% vs. PY Y T D (2) (2) (2)

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Q3 FY 25 Q3 FY 24 % Chg YTD FY 25 YTD FY 24 % Chg Total Revenue 290.3$ 282.7$ 2.7% 841.2$ 848.4$ (0.8%) Gross Margin 161.0 157.9 2.0% 464.5 472.6 (1.7%) % Margin 55.5% 55.9% 55.2% 55.7% A&M 37.9 39.5 (3.9%) 118.7 115.8 2.5% % Total Revenue 13.1% 14.0% 14.1% 13.6% G&A 26.2 26.0 0.7% 81.2 79.7 1.8% % Total Revenue 9.0% 9.2% 9.6% 9.4% D&A (ex. COGS) 5.0 5.6 (12.0%) 16.2 16.9 (3.8%) Operating Income 92.0$ 86.8$ 5.9% 248.3$ 260.3$ (4.6%) % Margin 31.7% 30.7% 29.5% 30.7% Adj. Diluted EPS (3) 1.22$ 1.06$ 15.1% 3.20$ 3.19$ 0.3% EBITDA 98.5$ 93.8$ 5.0% 270.0$ 283.4$ (4.7%) % Margin 33.9% 33.2% 32.1% 33.4% 3 Months Ended YTD FY25 Comments FY25 Third Quarter and YTD Consolidated Financial Summary ◼ Organic Revenue(1) down 0.9% vs. prior year – Clear Eyes sales aligned to expectations – International segment up 6% excluding currency – North America Women’s Health category performance up y/y in Q3 – Double-digit growth in eCommerce ◼ Gross Margin of 55.2% thanks to stable Q3 performance ◼ A&M of 14.1% of Revenue, as expected ◼ G&A of 9.6% of Revenue, as expected ◼ Adj. Diluted EPS(2) up slightly vs. prior year Dollar values in millions, except per share data 9 9 Months Ended

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S $63.5 $184.9 $69.5 $175.6 Free Cash Flow Free Cash Flow Free Cash Flow(2) Comments ◼ YTD FY25 Free Cash Flow(2) of $184.9 million up 5% vs. prior year – Maintaining full-year free cash flow outlook(4) of $240 million or more – Strong business attributes continue to drive Free Cash Flow ◼ Net Debt at December 31 of $0.9 billion(2); leverage ratio(3) of 2.5x ◼ Repurchased approximately 600,000 shares YTD for $40 million ◼ Robust Free Cash Flow enables further strategic capital deployment flexibility going forward Industry Leading Free Cash Flow Trends (8.6%) Dollar values in millions 10 5.3% Q3 FY25 Q3 FY24 YTD FY25 YTD FY24

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S III. FY25 Outlook

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Raising FY 25 Earnings Outlook ◼ Remain well-positioned in dynamic macro environment ◼ Continue to emphasize brand-building on leading brands ◼ Revenues of $1,128 to $1,132 million — Organic growth of approximately 1% ex-FX ◼ Adjusted Diluted EPS(5) of approximately $4.50 – Increased outlook driven by robust free cash flow and resulting lower interest ◼ Expect earnings growth acceleration to continue in Q4 ◼ Free Cash Flow(4) of $240 million or more ◼ Capital allocation decisions focused on maximizing shareholder value Top Line Trends Free Cash Flow & Allocation EPS 12

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Q&A

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated February 6, 2025 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Diluted EPS, EBITDA & EBITDA Margin, Free Cash Flow, and Net Debt are Non GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated February 6, 2025 in the “About Non-GAAP Financial Measures” section. (3) Leverage ratio reflects net debt / covenant defined EBITDA. (4) Free Cash Flow for FY25 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our earnings release dated February 6, 2025 in the “About Non-GAAP Financial Measures” section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures. (5) Adjusted Diluted EPS for FY25 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Diluted EPS in our earnings release dated February 6, 2025 in the “About Non-GAAP Financial Measures” section and is calculated based on projected GAAP Diluted EPS adjusted for certain discrete tax items. 14

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S EBITDA Margin 15 Reconciliation Schedules Organic Revenue Change

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S 16 Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS Adjusted Free Cash Flow (a) Income tax adjustment to adjust for discrete income tax items.

 
T H I R D Q U A R T E R F Y 2 5 R E S U L T S 17 Reconciliation Schedules (Continued) Projected Adjusted EPS Projected Free Cash Flow (a) Income tax adjustment to adjust for discrete income tax items. Projected FY'25 GAAP Diluted EPS 4.58$ Adjustments: Normalized tax rate adjustment (a) (0.08) Projected FY'25 Non-GAAP Adjusted EPS 4.50$

 
v3.25.0.1
Cover
Feb. 06, 2025
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 06, 2025
Entity Registrant Name PRESTIGE CONSUMER HEALTHCARE INC.
Entity Central Index Key 0001295947
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-32433
Entity Tax Identification Number 20-1297589
Entity Address, Address Line One 660 White Plains Road
Entity Address, City or Town Tarrytown
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10591
City Area Code 914
Local Phone Number 524-6800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol PBH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Prestige Consumer Health... (NYSE:PBH)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Prestige Consumer Health...
Prestige Consumer Health... (NYSE:PBH)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Prestige Consumer Health...